Co-Authors
This is a "connection" page, showing publications co-authored by Debra Richardson and Kathleen Moore.
Connection Strength
0.383
-
Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancer. Gynecol Oncol. 2024 Mar 05; 185:186-193.
Score: 0.224
-
Angiopoietin-1 and Angiopoietin-2 Inhibitors: Clinical Development. Curr Oncol Rep. 2019 02 26; 21(3):22.
Score: 0.159